Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H29Cl2N3OS |
| Molecular Weight | 418.424 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCN(CCN)CCCSCC(=O)C1(CCC1)C2=CC(Cl)=C(Cl)C=C2
InChI
InChIKey=OLQJWCYRPYGTJI-UHFFFAOYSA-N
InChI=1S/C19H29Cl2N3OS/c20-16-4-3-15(13-17(16)21)19(5-1-6-19)18(25)14-26-12-2-9-24(10-7-22)11-8-23/h3-4,13H,1-2,5-12,14,22-23H2
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
BTS 74,398
Created by
admin on Sat Dec 16 01:32:33 GMT 2023 , Edited by admin on Sat Dec 16 01:32:33 GMT 2023
|
PRIMARY | BTS 74,398 is a centrally acting stimulant drug which was developed for the treatment of Parkinson's disease. It inhibits the synaptic reuptake of dopamine, serotonin and noradrenaline, making it a triple reuptake inhibitor. It was effective in animal models of Parkinson's disease, but was unsuccessful in human trials. | ||
|
24838024
Created by
admin on Sat Dec 16 01:32:33 GMT 2023 , Edited by admin on Sat Dec 16 01:32:33 GMT 2023
|
PRIMARY | |||
|
I3W0WCC63A
Created by
admin on Sat Dec 16 01:32:33 GMT 2023 , Edited by admin on Sat Dec 16 01:32:33 GMT 2023
|
PRIMARY | |||
|
548491-50-5
Created by
admin on Sat Dec 16 01:32:33 GMT 2023 , Edited by admin on Sat Dec 16 01:32:33 GMT 2023
|
PRIMARY | |||
|
DTXSID801027130
Created by
admin on Sat Dec 16 01:32:33 GMT 2023 , Edited by admin on Sat Dec 16 01:32:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
